CACNB4: A Potential Drug Target and Biomarker (G785)

Target Name: CACNB4

NCBI ID: G785

CACNB4

CACNB4: A Potential Drug Target and Biomarker

CACNB4 (CACNB4 variant 2) is a protein that is expressed in the nervous system and has been identified as a potential drug target or biomarker. The protein is composed of 216 amino acids and has a calculated molecular weight of 23.9 kDa. It is localized to the endoplasmic reticulum and is expressed in various tissues, including the brain, heart, and skeletal muscles.

CACNB4 is involved in the regulation of neural transmission, which is critical for the function of the nervous system. It is a component of the neurotransmitter transporter, which is responsible for transporting neurotransmitters from the axon to the dendrites of neurons. It is also involved in the regulation of ion channels, which are responsible for the flow of electrical signals through the nervous system.

One of the unique features of CACNB4 is its ability to interact with several different neurotransmitters, including dopamine, serotonin, and GABA. This makes it a promising target for drugs that are designed to modulate these neurotransmitters. CACNB4 is also known to play a role in the regulation of pain perception, which is an important biomarker for several diseases, including chronic pain and neurodegenerative disorders.

In addition to its role in neural transmission and pain perception, CACNB4 is also involved in the regulation of several other cellular processes. For example, it is involved in the regulation of cell survival, cell proliferation, and cell migration. the regulation of inflammation, which is important for the development and progression of several diseases, including neuroinflammatory disorders.

CACNB4 is also a good candidate for a biomarker in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be a hallmark of these diseases. CACNB4 has been shown to be expressed in the brains of individuals with Alzheimer's disease and may be a potential biomarker for this condition.

In conclusion, CACNB4 is a protein that is expressed in the nervous system and has been identified as a potential drug target or biomarker. Its role in neural transmission, pain perception, and other cellular processes makes it a promising target for drugs that are designed to modulate these processes. In addition to its potential drug-targeting properties, CACNB4 is also a good candidate for a biomarker in neurodegenerative diseases. Further research is needed to fully understand the role of CACNB4 in these conditions and to develop effective treatments.

Protein Name: Calcium Voltage-gated Channel Auxiliary Subunit Beta 4

Functions: The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting

The "CACNB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets